[1]董小久 习玲.肌少症筛查测试与老年心力衰竭的研究进展[J].心血管病学进展,2021,(4):360-363.[doi:10.16806/j.cnki.issn.1004-3934.2021.04.017]
 DONG Xiaojiu,XI Ling.Research Progress on Screening Test of Sarcopenia and Heart Failure in the Elderly[J].Advances in Cardiovascular Diseases,2021,(4):360-363.[doi:10.16806/j.cnki.issn.1004-3934.2021.04.017]
点击复制

肌少症筛查测试与老年心力衰竭的研究进展()
分享到:

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2021年4期
页码:
360-363
栏目:
综述
出版日期:
2021-04-25

文章信息/Info

Title:
Research Progress on Screening Test of Sarcopenia and Heart Failure in the Elderly
作者:
董小久1 习玲2
(1.山西医科大学第一医院,山西 太原 030000;2.山西医科大学第一医院老年病科,山西 太原 030000)
Author(s):
DONG Xiaojiu 1XI Ling 2
(1.The First Hospital of Shanxi Medical University, Shanxi,Taiyuan 030000 ;2. Department of Geriatrics, The First Hospital of Shanxi Medical University , Shanxi,Taiyuan 030000)
关键词:
arial helvetica sans-serif text-align: center text-indent: 32.1333px">肌少症筛查老年人慢性心力衰竭
Keywords:
SarcopeniaScreeningThe elderlyChronic heart failure
DOI:
10.16806/j.cnki.issn.1004-3934.2021.04.017
摘要:
近年来,对于肌少症的临床研究已在国际上迅速发展。肌少症主要表现为年龄增长性的骨骼肌质量、力量和功能的降低,是老年心力衰竭患者的重要并发症,严重影响患者的预后,而心力衰竭又可能增加肌少症的患病率。因此,早期筛查肌少症对预防老年心力衰竭患者不良事件发生的风险及改善生活质量及预后至关重要。
Abstract:
In recent years,the clinical research on sarcopenia has developed rapidly in the world. Sarcopenia is mainly manifested as age-related deterioration of skeletal muscle mass,strength and function. It is an important complication of elderly patients with heart failure,which seriously affects the prognosis of patients,and heart failure may increase the prevalence of sarcopenia. Therefore,early screening of sarcopenia is very important to prevent the risk of adverse events and improve the quality of life and prognosis of elderly patients with heart failure.

参考文献/References:

[1].Fülster S,Tacke M,Sandek A,et al. Muscle wasting in patients with chronic heart failure: results from the studies investigating co-morbidities aggravating heart failure (SICA-HF)[J]. Eur Heart J2013,34(7):512-519.
[2].Cruz-Jentoft AJ,Baeyens JP,Bauer JM,et al. Sarcopenia:European consensus on definition and diagnosis:Report of the European Working Group on Sarcopenia in Older People[J]. Age Aging, 2010,39(4):412-423.
[3].Chen LK,Liu LK,Woo J,et al. Sarcopenia in Asia:consensus report of the Asian Working Group for Sarcopenia[J].?J Am Med Dir Assoc,2014,15(2):95-101.
[4].Chen LK,Woo J,Assantachai P,et al. Asian Working Group for Sarcopenia:2019 Consensus Update on Sarcopenia Diagnosis and Treatment[J]. J Am Med Dir Assoc,2020,21(3):300-307.
[5].Malmstrom TK,Morley JE. SARC-F:a simple questionnaire to rapidly diagnose sarcopenia[J]. J Am Med Dir Assoc,2013,14(8):531-532.
[6].王晓英. 老年肌少症问卷的汉化及运动疗法对肌少症治疗效果的meta分析[D]. 河北医科大学,2018.
[7].Cao L,Chen S,Zou C,et al. A pilot study of the SARC-F scale on screening sarcopenia and physical disability in the Chinese older people[J]. J Nutr Health Aging,2014,18(3):277-283.
[8].Malmstrom TK,Miller DK, Simonsick EM,et al. SARC-F:a symptom score to predict persons with sarcopenia at risk for poor functional outcomes[J]. J Cachexia Sarcopenia Muscle,2016,7(1):28-36.
[9].Kotlarczyk MP,Perera S,Nace DA,et al. Identifying sarcopenia in female long-term care residents: a comparison of current guidelines[J].?J Am Geriatr Soc,2018,66(2):316-320.
[10].Rolland Y,Dupuy C,Abellan Van Kan G,et al. Sarcopenia screened by the SARC-F questionnaire and physical performances of elderly women:a cross-sectional study[J].?J Am Med Dir Assoc,2017,18(10):848-852.
[11].Urzi F,?imuni? B,Buzan E. Basis for sarcopenia screening with the SARC-CalF in nursing homes[J]. J Am Med Dir Assoc,2017,18(11):991.e5-991.e10.
[12].Barbosa-Silva TG,Menezes AM,Bielemann RM,et al. Enhancing SARC-F:improving sarcopenia screening in the clinical practice[J]. J Am Med Dir Assoc,2016,17(12):1136-1141.
[13].Morley JE,Anker SD,von Haehling S. Prevalence,incidence,and clinical impact of sarcopenia:facts,numbers,and epidemiology—update 2014[J]. J Cachexia Sarcopenia Muscle,2014,5(4):253-259.
[14].Chen LK,Lee WJ,Peng LN,et al. Recent Advances in Sarcopenia Research in Asia:2016 Update From the Asian Working Group for Sarcopenia[J]. J Am Med Dir Assoc,2016:17(8):767.e1-e7.?
[15].Bekfani T,Pellicori P,Morris DA,et al. Sarcopenia in patients with heart failure with preserved ejection fraction: Impact on muscle strength, exercise capacity and quality of life[J]. Int J Cardiol,2016,222:41-46.
[16].[16]Valentova M,Anker SD,von Haehling S. Cardiac cachexia revisited:the role of wasting in heart failure[J]. Heart Fail Clin,2020,16(1):61-69.
[17].[17]Azhar G,Wei JY. New approaches to treating cardiac cachexia in the older patient[J]. Curr Cardiovasc Risk Rep,2013,7(6):480-484.
[18].[18]Haykowsky MJ,Brubaker PH,Morgan TM,et al. Impaired aerobic capacity and physical functional performance in older heart failure patients with preserved ejection fraction: role of lean body mass[J]. J Gerontol A Biol Sci Med Sci,2013,68(8):968-975.
[19].[19]von Haehling S,Garfias Macedo T,Valentova M,et al. Muscle wasting as an independent predictor of survival in patients with chronic heart failure[J]. J Cachexia Sarcopenia Muscle,2020,11(5):1242-1249.?
[20].[20]Saitoh M,Ishida J,Doehner W,et al. Sarcopenia,cachexia,and muscle performance in heart failure:review update 2016[J]. Int J Cardiol,2017,238:5-11.
[21].[21]Dos Santos MR,Sayegh AL,Bacurau AV,et al. Effect of exercise training and testosterone replacement on skeletal muscle wasting in patients with heart failure with testosterone deficiency[J]. Mayo Clin Proc,2016,91(5):575-586.
[22].[22]von Haehling S,Ebner N,Dos Santos MR,et al. Muscle wasting and cachexia in heart failure:mechanisms and therapies[J]. Nat Rev Cardiol,2017,14(6):323-341.
[23].[23]王永春,蒲荣喜,杨忠.增龄性骨骼肌减少症的细胞及分子机制研究[J].中国老年学杂志,2016,36(11):2799-2802.
[24].[24]Mankhong S,Kim S,Moon S,et al. Experimental models of sarcopenia: bridging molecular mechanism and therapeutic strategy[J]. Cells,2020,9(6):1385.
[25].[25]Adams V,Linke A. Impact of exercise training on cardiovascular disease and risk[J].?Biochim Biophys Acta Mol Basis Dis,2019,1865(4):728-734.
[26].[26]Liguori I,Russo G,Aran L,et al. Sarcopenia:assessment of disease burden and strategies to improve outcomes[J]. Clin Interv Aging,2018,13:913-927.
[27].[27]Suzuki T,Palus S,Springer J,et al. Skeletal muscle wasting in chronic heart failure[J]. ESC Heart Fail,2018,5(6):1099-1107.
[28].[28] Naseeb MA,Volpe SL. Protein and exercise in the prevention of sarcopenia and aging[J]. Nutr Res,2017,40:1-20.
[29].[29]Pasiakos SM,McClung HL,McClung JP,et al. Leucine-enriched essential amino acid supplementation during moderate steady state exercise enhances postexercise muscle protein synthesis[J]. Am J Clin Nutr,2011,94(3):809-818.
[30].[30]Dupont J,Dedeyne L,Dalle S,et al. The role of omega-3 in the prevention and treatment of sarcopenia[J].?Aging Clin Exp Res,2019,31(6):825-836.
[31].[31]Sumukadas D,Witham MD,Struthers AD,et al. Effect of perindopril on physical function in elderly people with functional impairment: a randomized controlled trial[J]. CMAJ,2007,177(8):867-874.
[32].[32]Zhou LS,Xu LJ,Wang XQ,et al. Effect of angiotensin-converting enzyme inhibitors on physical function in elderly subjects:a systematic review and meta-analysis [J].?Drugs Aging,2015,32(9):727-735.
[33].[33]Brioche T,Kireev RA,Cuesta S,et al. Growth hormone replacement therapy prevents sarcopenia by a dual mechanism:improvement of protein balance and of antioxidant defenses[J]. J Gerontol A Biol Sci Med Sci,2014,69(10):1186-1198.
[34].[34]Temel JS,Abernethy AP,Currow DC,et al. Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2):results from two randomised,double-blind,phase 3 trials[J]. Lancet Oncol,2016,17(4):519-531.
[35].[35]Rooks D,Praestgaard J,Hariry S,et al. Treatment of sarcopenia with bimagrumab:results from a phase II,randomized,controlled,proof‐of‐concept study[J]. J Am Geriatr Soc,2017,65(9):1988-1995.

备注/Memo

备注/Memo:
通信作者:习玲,E-mail:xiling9002@163.com
收稿日期:2020-09-27
更新日期/Last Update: 2021-07-01